IBM (NYSE:IBM) has big plans for its Watson artificial-intelligence computer. Money-making plans, that is, especially in the fields of finance and health care.
Motley Fool analysts Rex Moore and Max Macaluso chatted with Pristine co-founder Kyle Samani at the recent mHealth Summit near Washington, D.C. Samani believes IBM's Watson and similar approaches to "predictive analytics" will eventually make major contributions to the health care field, although they're not currently generating any real-world value.
A full transcript follows the video.
The Motley Fool's top stock in 2014
There’s a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it’s one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
Max Macaluso: Do you have any thoughts on the IBM Watson project?
Kyle Samani: I do have some thoughts on it. I actually know quite a bit about it; I've done some good research, and I know a lot of people who work on the teams and I've spoken with them. I think the vision is very compelling and very ambitious. I love it.
Today, it's effectively doing nothing, in the real world. The real world value being generated is nothing. There's a lot of major medical centers investing a lot in Watson -- or I should say with IBM -- because they believe in that vision, and I applaud them for doing so.
I'm optimistic that, in time, it will happen. Telling you if that's going to be 3 years or 8 years or 15 years? I have no ability to assess that today. No one does, including anyone on the Watson team. The technical side, I suspect, will solve itself. The harder problem is probably the regulatory side, and I'm not sure what to make of how that will play itself out.
I fully expect Watson -- or Watson-like technologies; let's just call them "predictive analytics" -- will become a major part of the future of health care delivery, but it's still a long ways off. There's a lot that needs to be done first.
Max Macaluso, Ph.D. has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. Rex Moore has no position in any stocks mentioned. The Motley Fool owns shares of International Business Machines. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.